The ‘Field Hypothesis’: rebound activity after stopping disease-modifying therapies
- 1 July 2017
- journal article
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 15, A1-A2
Abstract
No abstract availableThis publication has 18 references indexed in Scilit:
- Disease reactivation following fingolimod withdrawal in multiple sclerosis: Two case reportsMultiple Sclerosis and Related Disorders, 2017
- Switching patients at high risk of PML from natalizumab to another disease-modifying therapyPractical Neurology, 2016
- Dramatic recovery of steroid-refractory relapsed multiple sclerosis following Fingolimod discontinuation using selective immune adsorptionBMC Neurology, 2015
- Natalizumab to fingolimod washout in patients at risk of PMLNeurology, 2014
- Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapyMultiple Sclerosis Journal, 2013
- Multiple sclerosis rebound following herpes zoster infection and suspension of fingolimodNeurology, 2012
- Reconstitution of circulating lymphocyte counts in FTY720-treated MS patientsClinical Immunology, 2010
- Mechanism of Action of Oral Fingolimod (FTY720) in Multiple SclerosisClinical Neuropharmacology, 2010
- Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse modelImmunology, 2009
- Magnetization transfer changes in the normal appering white matter precede the appearance of enhancing lesions in patients with multiple sclerosisAnnals of Neurology, 1998